Hahn, Felix; Mueller, Lukas; Jungmann, Florian et al.
Survival prediction for patients with non-resectable intrahepatic cholangiocarcinoma undergoing chemotherapy: a retrospective analysis comparing the tumor marker CA 19-9 with cross-sectional imagingJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2020
Kaps, Leonard; Grambihler, Annette; Yemane, Bethlehem et al.
Symptom Burden and Treatment Response in Patients with Primary Biliary Cholangitis (PBC)DIGESTIVE DISEASES AND SCIENCES. Bd. 65. H. 10. 2020 S. 3006-3013
Triantafyllias, K.; Klonowski, A.; Cavagna, L. et al.
SYSTEMATIC CORONARY RISK EVALUATION (SCORE) MISCLASSIFIES CARDIOVASCULAR RISK IN ANTISYNTHETASE SYNDROME: RESULTS OF THE PILOT MULTICENTRIC STUDY RI.CARDAANNALS OF THE RHEUMATIC DISEASES. Bd. 79. 2020 S. 411-411
Douglas, R. S.; Kahaly, G. J.; Patel, A. et al.
Teprotumumab for the Treatment of Active Thyroid Eye DiseaseNEW ENGLAND JOURNAL OF MEDICINE. Bd. 382. H. 4. 2020 S. 341-352
Schmidt, Benjamin Christopher; Sivanathan, Visvakanth; Schmiedel, Stefan et al.
The Ambulatory Management of COVID-19 Via the German Department of HealthDEUTSCHES ARZTEBLATT INTERNATIONAL. Bd. 117. H. 29-30. 2020 S. 507-508
Newsome, P.; Schattenberg, J.; Serfaty, L. et al.
The economic cost and health burden of non-alcoholic steatohepatitis in the EU5 countriesDIGESTIVE AND LIVER DISEASE. Bd. 52. 2020 S. E33-E34
Newsome, P.; Schattenberg, J.; Serfaty, L. et al.
THE ECONOMIC COST AND HEALTH BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS IN THE EU5 COUNTRIESDIGESTIVE AND LIVER DISEASE. Bd. 52. 2020 S. S166-S167
Hardy, Timothy; Wonders, Kristy; Younes, Ramy et al.
The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver diseaseCONTEMPORARY CLINICAL TRIALS. Bd. 98. 2020
Huber, Yvonne; Schattenberg, Joern M.
The new Focus on Metabolic Liver Diseases at UM Mainz is introducedGASTROENTEROLOGE. Bd. 15. H. 4. 2020 S. 343-345
Drenth, Joost P. H.; Schattenberg, Joern M.
The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future successEXPERT OPINION ON INVESTIGATIONAL DRUGS. Bd. 29. H. 12. 2020 S. 1365-1375